Vemurafenib (720 mg for 28 days, as an off-label drug) was first tested on a 12-year-old Caucasian boy with a right frontoparietal GBM (BRAF V600E) treated with conventional modalities, who developed tumour recurrence 2.5 years from diagnosis [84]. Here, BRAF is linked to neoplasm.